SOUTH SAN FRANCISCO, Calif. , March 24, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics , Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody ® technology

-Broad advancement of clinical pipeline- -Three-arm Phase 2 study of praluzatamab ravtansine (CX-2009) launched in breast cancer- -Enrollment continues in Phase 2 expansion study of CX-2029 in four cancer types, in partnership with AbbVie- -Bristol Myers Squibb expands anti-CTLA-4 Probody Program

SOUTH SAN FRANCISCO, Calif. , Feb. 22, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics , Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally-active antibody therapeutics based on its Probody ® technology platform,

SOUTH SAN FRANCISCO, Calif. , Feb. 19, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally-active antibody therapeutics based on its Probody ® technology platform,

SOUTH SAN FRANCISCO, Calif. , Feb. 17, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally-active antibody therapeutics based on its Probody ® technology platform,

SOUTH SAN FRANCISCO, Calif. , Feb. 04, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics , Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody ® technology platform, today announced that

SOUTH SAN FRANCISCO, Calif. , Feb. 03, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics , Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies, today announced that it has issued and sold an additional

SOUTH SAN FRANCISCO, Calif. , Jan. 26, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics , Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies, today announced the completion of its previously announced

SOUTH SAN FRANCISCO, Calif. , Jan. 20, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics , Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies, today announced the pricing of an underwritten public

SOUTH SAN FRANCISCO, Calif. , Jan. 19, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies, today announced that it has commenced an underwritten